NCT03960502View on ClinicalTrials.gov

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

September 7, 2019

Study Completion Date

September 7, 2019

Conditions
Healthy Male Participants
Interventions
DRUG

AG-881

Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.

DRUG

[13C315N3]AG-881

Single IV microdose of approximately 100 μg.

Trial Locations (1)

53704

Covance Clinical Research Unit Inc., Madison

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY